Emyria (ASX:EMD)

Emyria (ASX:EMD) is a clinical stage biotech company founded in 2018 and headquartered in Australia. The company operates with the slogan "A clinical stage biotech informed by patient experience. Tackling unmet needs in neuroscience & mental health #RealWorld." Emyria Limited is focused on improving patient outcomes in neuroscience and mental health through a unique business model. The company's operations are divided into three main segments. Firstly, Emyria Clinics offer evidence-based and emerging therapies for mental health and other unmet needs across multiple sites. Secondly, Emyria Data provides robust and ethically-sourced Real-World Data gathered with patients, which is utilized to enhance Emyria’s distinct therapy and drug development programs. Lastly, Emyria Drug Discovery possesses one of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia, along with a suite of high potency Ultra-Pure cannabinoids that are currently being evaluated in clinical trials for a range of mental health and select neuroscience indications. The company recently secured a $5.00MPost-IPO Equity investment on 22 November 2021 from Tattarang. Emyria's focus on utilizing real-world data to improve patient outcomes and its innovative drug discovery programs position it as a promising player in the healthcare and pharmaceutical industries.